Annual Report Confirms Going Concern Doubt, NYSE Delisting, and Material Internal Control Weaknesses
RBOT sits 37% above its 52-week low of $0.27.
Summary
Vicarious Surgical's 10-K reveals substantial doubt about its ability to continue as a going concern, confirms its NYSE delisting, and discloses material weaknesses in internal controls, painting a grim financial picture.
Key Events · Corporate Governance and Compliance · RBOT
-
Substantial Doubt About Going Concern
Management and the independent auditor (Cherry Bekaert LLP) have expressed substantial doubt about the company's ability to continue as a going concern, citing recurring losses and insufficient cash to fund operations beyond Q2 2026.
-
NYSE Delisting Confirmed
The company confirmed its Class A common stock was immediately suspended from trading and delisted from the NYSE on March 3, 2026, due to failing to maintain the minimum $15 million average market capitalization. Trading has transitioned to the OTCID market tier.
-
Significant Net Loss and Cash Burn
Reported a net loss of $50.182 million for the year ended December 31, 2025, and net cash used in operating activities of $45.076 million, indicating continued high cash burn relative to its market capitalization.
-
Material Weaknesses in Internal Controls
Identified material weaknesses in internal control over financial reporting for 2025 and 2024, related to insufficient accounting resources, ineffective risk assessment, improper segregation of duties, and IT controls.
Analysis · RBOT · Industrial Applications And Services
This annual report provides a comprehensive and audited view of Vicarious Surgical's dire financial state, confirming previous announcements and adding critical details. The explicit 'going concern' warning from both management and the auditor highlights severe liquidity issues, with current cash and investments insufficient to fund operations for the next 12 months. The confirmed NYSE delisting and transition to OTCID will further impair liquidity and the ability to raise capital. The disclosure of material weaknesses in internal controls indicates significant operational and financial reporting risks. While some events were pre-announced in 8-Ks, this 10-K provides the full, detailed, and audited context, underscoring the company's precarious position and the substantial challenges to its future viability.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RBOT was trading at $0.37 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $0.27 to $13.75. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.